(Total Views: 392)
Posted On: 07/01/2019 9:54:06 AM
Post# of 153916
Based on AACR 2019 presentation, it sounds like we will be using Menarini Silicon Biosystems CELLSEARCH® Circulating Tumor Cell (CTC) test for cancer.
RP and Dr. Cristofanilli (Father of CTCs) have a history and share the CTC patent together. You likely already know this, so just sharing for others who may not be aware.
https://patents.google.com/patent/WO2016209926A1/en
Extract from AACR 2019 CTC Presentation
It is never a bad thing to have too much data....maybe they will use both tests....occupancy test to determine dosage (even though RP has said they anticipate using 700 mg if well tolerated) and then the CELLSEARCH for initial and 21 days CTC level tests?
RP and Dr. Cristofanilli (Father of CTCs) have a history and share the CTC patent together. You likely already know this, so just sharing for others who may not be aware.
https://patents.google.com/patent/WO2016209926A1/en
Extract from AACR 2019 CTC Presentation
It is never a bad thing to have too much data....maybe they will use both tests....occupancy test to determine dosage (even though RP has said they anticipate using 700 mg if well tolerated) and then the CELLSEARCH for initial and 21 days CTC level tests?
(2)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
